| | | Trump’s 63 Million Doses of Hydroxychloroquine Could Have Been Great for America
By David Gortler
Dr. David Gortler is a pharmacologist and pharmacist. He is a former Yale University School of Medicine professor of pharmacology and biotechnology. While at Yale, he was recruited by the FDA to become a medical officer/senior medical analyst in the FDA’s Office of New Drugs. He was later appointed as senior advisor to the FDA commissioner on drug safety and FDA science policy.
brownstone.org
malone.news
Highlights:
After Trump pressured the FDA into granting HCQ an Emergency Use Authorization, they wanted to push it aside in favor of Remdesovir. So they set up a bogus study designed to make HCQ look dangerous.
- 2 to 6 times the recommended maximum maintenance dose of HCQ
- did not screen for well-known drug-drug interactions
As a result, patients died. They used that excuse to cancel the EUA for HCQ.
====================================
At the same time the FDA declared HCQ "unsafe" for short term use, CDC's official stance was that it was safe for long term use, even for children and pregnant mothers. It is, of course, impossible for both of those to be true.
====================================
HCQ had a few adverse events reported to FAERS. FDA relied on those reports to declare HCQ unsafe. The same FDA said FAERS was totally unreliable when it came to the Covid vaccine.
There have been 37,000 deaths caused by the Covid vaccine, more than all adverse events of any kind for HCQ in 50 years. In just a few year, FAERS has logged 1 million adverse events for the Covid vaccine.
====================================
Prior to HCQ’s EUA removal, a highly coordinated message came out against HCQ from the American press, making it appear that Trump’s HCQ recommendation was not only “unsafe” but that it also “didn’t work” for Covid-19.
Harvard, Stanford, and Scripps Institute scientists warned Americans via a Washington Post article that Trump’s efforts to employ HCQ were “desperate” and “If there was ever hope for [HCQ], this is the death of it” and “It’s one thing not to have benefit, but [HCQ] shows distinct harm.”
The scientists quoted above were referencing Lancet and New England Journal of Medicine articles that were widely referenced as a means to criticize Trump’s proposal for implementation of HCQ for Covid-19. Both publications were later retracted by journal editors due to being fraudulent. ====================================
Any antibiotic, antifungal, antiviral drug is substantially less efficacious when it’s implemented during the late-stages of infections, at which point the rapidly replicating infection would overwhelm an individual. Early/immediate treatment is the clinical standard for the treatment of all viral infections, regardless if the virus is: influenza, cold sores, HIV, or Covid-19.
Curiously, the two most prestigious HCQ trials (Solidarity, Recovery) focused on late treatment. Clearly, they were designed to fail.
====================================
Remdsivir does not work, but Medicare gave hospitals an extra $100,000 per patient if they used Remdesivir:
The SOLIDARITY trial showed that remdesivir did not reduce mortality or decrease the time that it took for patients to recover from Covid-19. The preponderance of the cumulative, up-to-date findings illustrates that there are no statistically significant or clinically meaningful improvements with remdesivir use. In the few positive studies, the small non-significant mortality improvement disappears with longer follow-up duration.
Despite all of that, hospitals were financially incentivized to entice patients to use remdesivir by granting a mysterious 20% “boost” bonus payment from Medicare on the entire hospital bill for those patients who agreed to receiving remdesivir and larger bonus payment to the hospital if a Covid-19 patient is mechanically ventilated. In the end, that worked out to each hospital receiving “at least” a $100,000 “bonus” per patient, paid for by American tax dollars. ====================================
Paxlovid does not work:
According to the most recent findings, Paxlovid doesn’t work, even if you double the length of dosing according to the most recent and cumulative findings published in the July 2024 issue of the New England Journal of Medicine.
It reconfirms an earlier published case report just weeks after Paxlovid was approved and given to Americans showing that people who take Paxlovid don’t get better sooner, compared to those taking placebo. The medical community has known, and written about Paxlovid rebound which occurred from the very beginning.
Tom |
|
